Double-blind, randomized, placebo-controlled study to evaluate the effects of tegaserod on gastric motor, sensory and myoelectric function in healthy volunteers

N. J. Talley, Michael Camilleri, D. Burton, G. Thomforde, K. Koch, M. J. Rucker, J. Peterson, A. R. Zinsmeister, D. L. Earnest

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: The effects of tegaserod on gastric accommodation and postprandial satiety remain unclear. Aim: To compare the effects of tegaserod 6 mg twice daily vs. placebo on gastric volumes, postprandial symptoms, gastric emptying, small bowel transit and the surface electrogastrogram in female and male healthy volunteers. Methods: Randomized, double-blind, placebo-controlled study evaluated gastric function before and after 7 days of tegaserod 6 mg twice daily (n = 21) vs. placebo (n = 20) in healthy volunteers. Validated methods were used to study gastric emptying, myoelectrical activity, volumes and satiation postnutrient challenge. Results: There were no significant effects of tegaserod on the primary endpoints assessing gastric function: emptying of solids or liquids, total gastric volumes or myoelectrical activity. Maximum tolerated volume and aggregate symptom score with nutrient challenge on placebo were 1035 mL (±44) and 130 (±15) vs. 989 mL (±43) and 117 (±15) during tegaserod, respectively (all P = N.S.). Postprandial change in proximal gastric volume by single photon emission-computed tomography was decreased in females on tegaserod (246 ± 30) vs. placebo (358 ± 32) (P = 0.015). Proximal fasting volumes in females were increased on tegaserod (126 ± 12) vs. placebo (92 ± 13) (P = 0.066). Conclusions: While tegaserod decreased proximal gastric volume change after a meal, it does not appear to have significant effects on gastric motor and sensory function in healthy individuals. Further studies are required in patients with disturbances of gastric motor and sensory function.

Original languageEnglish (US)
Pages (from-to)859-867
Number of pages9
JournalAlimentary Pharmacology and Therapeutics
Volume24
Issue number5
DOIs
StatePublished - Sep 2006

Fingerprint

Stomach
Healthy Volunteers
Placebos
Gastric Emptying
Satiation
tegaserod
Single-Photon Emission-Computed Tomography
Double-Blind Method
Meals
Fasting
Food

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Double-blind, randomized, placebo-controlled study to evaluate the effects of tegaserod on gastric motor, sensory and myoelectric function in healthy volunteers. / Talley, N. J.; Camilleri, Michael; Burton, D.; Thomforde, G.; Koch, K.; Rucker, M. J.; Peterson, J.; Zinsmeister, A. R.; Earnest, D. L.

In: Alimentary Pharmacology and Therapeutics, Vol. 24, No. 5, 09.2006, p. 859-867.

Research output: Contribution to journalArticle

Talley, N. J. ; Camilleri, Michael ; Burton, D. ; Thomforde, G. ; Koch, K. ; Rucker, M. J. ; Peterson, J. ; Zinsmeister, A. R. ; Earnest, D. L. / Double-blind, randomized, placebo-controlled study to evaluate the effects of tegaserod on gastric motor, sensory and myoelectric function in healthy volunteers. In: Alimentary Pharmacology and Therapeutics. 2006 ; Vol. 24, No. 5. pp. 859-867.
@article{c153fdf978a04851b12584b05415945b,
title = "Double-blind, randomized, placebo-controlled study to evaluate the effects of tegaserod on gastric motor, sensory and myoelectric function in healthy volunteers",
abstract = "Background: The effects of tegaserod on gastric accommodation and postprandial satiety remain unclear. Aim: To compare the effects of tegaserod 6 mg twice daily vs. placebo on gastric volumes, postprandial symptoms, gastric emptying, small bowel transit and the surface electrogastrogram in female and male healthy volunteers. Methods: Randomized, double-blind, placebo-controlled study evaluated gastric function before and after 7 days of tegaserod 6 mg twice daily (n = 21) vs. placebo (n = 20) in healthy volunteers. Validated methods were used to study gastric emptying, myoelectrical activity, volumes and satiation postnutrient challenge. Results: There were no significant effects of tegaserod on the primary endpoints assessing gastric function: emptying of solids or liquids, total gastric volumes or myoelectrical activity. Maximum tolerated volume and aggregate symptom score with nutrient challenge on placebo were 1035 mL (±44) and 130 (±15) vs. 989 mL (±43) and 117 (±15) during tegaserod, respectively (all P = N.S.). Postprandial change in proximal gastric volume by single photon emission-computed tomography was decreased in females on tegaserod (246 ± 30) vs. placebo (358 ± 32) (P = 0.015). Proximal fasting volumes in females were increased on tegaserod (126 ± 12) vs. placebo (92 ± 13) (P = 0.066). Conclusions: While tegaserod decreased proximal gastric volume change after a meal, it does not appear to have significant effects on gastric motor and sensory function in healthy individuals. Further studies are required in patients with disturbances of gastric motor and sensory function.",
author = "Talley, {N. J.} and Michael Camilleri and D. Burton and G. Thomforde and K. Koch and Rucker, {M. J.} and J. Peterson and Zinsmeister, {A. R.} and Earnest, {D. L.}",
year = "2006",
month = "9",
doi = "10.1111/j.1365-2036.2006.03049.x",
language = "English (US)",
volume = "24",
pages = "859--867",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Double-blind, randomized, placebo-controlled study to evaluate the effects of tegaserod on gastric motor, sensory and myoelectric function in healthy volunteers

AU - Talley, N. J.

AU - Camilleri, Michael

AU - Burton, D.

AU - Thomforde, G.

AU - Koch, K.

AU - Rucker, M. J.

AU - Peterson, J.

AU - Zinsmeister, A. R.

AU - Earnest, D. L.

PY - 2006/9

Y1 - 2006/9

N2 - Background: The effects of tegaserod on gastric accommodation and postprandial satiety remain unclear. Aim: To compare the effects of tegaserod 6 mg twice daily vs. placebo on gastric volumes, postprandial symptoms, gastric emptying, small bowel transit and the surface electrogastrogram in female and male healthy volunteers. Methods: Randomized, double-blind, placebo-controlled study evaluated gastric function before and after 7 days of tegaserod 6 mg twice daily (n = 21) vs. placebo (n = 20) in healthy volunteers. Validated methods were used to study gastric emptying, myoelectrical activity, volumes and satiation postnutrient challenge. Results: There were no significant effects of tegaserod on the primary endpoints assessing gastric function: emptying of solids or liquids, total gastric volumes or myoelectrical activity. Maximum tolerated volume and aggregate symptom score with nutrient challenge on placebo were 1035 mL (±44) and 130 (±15) vs. 989 mL (±43) and 117 (±15) during tegaserod, respectively (all P = N.S.). Postprandial change in proximal gastric volume by single photon emission-computed tomography was decreased in females on tegaserod (246 ± 30) vs. placebo (358 ± 32) (P = 0.015). Proximal fasting volumes in females were increased on tegaserod (126 ± 12) vs. placebo (92 ± 13) (P = 0.066). Conclusions: While tegaserod decreased proximal gastric volume change after a meal, it does not appear to have significant effects on gastric motor and sensory function in healthy individuals. Further studies are required in patients with disturbances of gastric motor and sensory function.

AB - Background: The effects of tegaserod on gastric accommodation and postprandial satiety remain unclear. Aim: To compare the effects of tegaserod 6 mg twice daily vs. placebo on gastric volumes, postprandial symptoms, gastric emptying, small bowel transit and the surface electrogastrogram in female and male healthy volunteers. Methods: Randomized, double-blind, placebo-controlled study evaluated gastric function before and after 7 days of tegaserod 6 mg twice daily (n = 21) vs. placebo (n = 20) in healthy volunteers. Validated methods were used to study gastric emptying, myoelectrical activity, volumes and satiation postnutrient challenge. Results: There were no significant effects of tegaserod on the primary endpoints assessing gastric function: emptying of solids or liquids, total gastric volumes or myoelectrical activity. Maximum tolerated volume and aggregate symptom score with nutrient challenge on placebo were 1035 mL (±44) and 130 (±15) vs. 989 mL (±43) and 117 (±15) during tegaserod, respectively (all P = N.S.). Postprandial change in proximal gastric volume by single photon emission-computed tomography was decreased in females on tegaserod (246 ± 30) vs. placebo (358 ± 32) (P = 0.015). Proximal fasting volumes in females were increased on tegaserod (126 ± 12) vs. placebo (92 ± 13) (P = 0.066). Conclusions: While tegaserod decreased proximal gastric volume change after a meal, it does not appear to have significant effects on gastric motor and sensory function in healthy individuals. Further studies are required in patients with disturbances of gastric motor and sensory function.

UR - http://www.scopus.com/inward/record.url?scp=33747329558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747329558&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2006.03049.x

DO - 10.1111/j.1365-2036.2006.03049.x

M3 - Article

VL - 24

SP - 859

EP - 867

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 5

ER -